Tshiab Immuno-oncology Therapy ONO-4685 Nkag mus rau Theem 1 Kev Kho Mob hauv Tebchaws Meskas

Lub tuam txhab tshuaj Nyij Pooj ONO Pharma' lub chaw muag khoom hauv Teb Chaws Asmeskas ONO Pharma USA tsis ntev los no tau tshaj tawm tias nws tau tshaj tawm theem 1 txoj kev tshawb fawb los ntsuas ONO-4685 hauv cov neeg mob uas rov qab los lossis refractory T-cell lymphoma hauv Tebchaws Meskas, uas yog ib qho tshuaj tiv thaiv PD. -1/CD3 bispecific antibody.

Txoj kev tshawb no yog ntau qhov chaw, qhib-label, koob tshuaj nce qib 1 txoj kev tshawb fawb (ONO-4685-03, NCT05079282), uas yog lub hom phiaj los ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm ONO-4685 hauv cov neeg mob uas rov qab los lossis refractory T-cell lymphoma.

Masahiro Katayama, Tus Thawj Coj ntawm Kev Txhim Kho Kev Kho Mob thiab Tus Lwm Thawj Coj ntawm ONO Pharma Tebchaws USA US/EU, tau hais tias:" Peb zoo siab heev los pib txoj kev tshawb fawb theem 1 ntawm ONO-4685, kev tiv thaiv PD-1 / CD3 bispecific antibody nrog ib tug tshiab mechanism ntawm kev txiav txim. Peb cia siab tias ONO-4685 yuav muaj ib hnub coj tau txiaj ntsig rau cov neeg mob rov qab los lossis rov ua dua tshiab T-cell lymphoma hauv Tebchaws Meskas."

T-cell lymphoma yog ib hom qog nqaij hlav uas tsis tshua muaj tshwm sim los ntawm cov qog nqaij hlav T-cells lossis cov neeg tua neeg ntuj (NK) hlwb, suav txog li 10-15% ntawm non-Hodgkin's lymphoma (NHL). T-cell lymphoma tuaj yeem tshwm sim hauv cov ntaub so ntswg lymphoid thiab / lossis cov ntaub so ntswg sab nraud, xws li daim siab, tawv nqaij, ntshav, thiab lwm yam. Cov subtypes ntawm T-cell lymphoma yog peripheral T-cell lymphoma (PTCL) thiab cutaneous T-cell lymphoma ( CTCL), thiab qhov kev mob tshwm sim phem dua li feem ntau B-cell NHL subtypes. Yog li ntawd, cov kev kho tshiab yuav tsum tau ua los txhim kho cov kev mob tshwm sim ntawm cov neeg mob T-cell lymphoma.

ONO-4685 yog ib qho tshuaj tiv thaiv-PD-1 / CD3 bispecific antibody tab tom tsim. Nws tshwj xeeb khi rau tib neeg PD-1 thiab CD3 thiab tau tsim los kho cov kab mob autoimmune thiab hematological malignancies.

PD-1 yog ib qho inhibitory receptor uas tau qhia tshwj xeeb thiab nce rau ntawm T cells thiab B hlwb. Tsis tas li ntawd, PD-1 tau nthuav tawm ntawm cov kab mob T-hlwb ntawm qee yam T cell lymphoma subtypes.

CD3 yog cov protein ntau ntawm T cell receptors. CD3 bispecific antibody therapy yog ib txoj hauv kev tshiab ntawm qog immunotherapy, uas tuaj yeem txuas T hlwb thiab cov qog nqaij hlav malignant, yog li inducing anti-tumor activating. Raws li cov ntaub ntawv tshawb fawb tsis yog tshuaj kho mob, ONO-4685 muaj peev xwm ua tau zoo rau T-cell lymphoma.